Berlin, 27 February 2008. The Eckert & Ziegler AG (ISIN DE 0005659700, based in Berlin), a specialist in tumor radiation systems und implants for cancer treatment has acquired a large order thus strengthening its market position as a supplier for radiation therapy products in Spain. The newly-founded Eckert & Ziegler Iberia S.L. based in Madrid succeeded in winning a tender for the long-term supply of various regional hospitals amounting to 0.7 million EUR.
"Spain is one of the largest European markets for brachytherapy products", explains Dr. Edgar Löffler, Executive Board member of the Eckert & Ziegler AG and Managing Director of Eckert & Ziegler Iberia S.L. "We are glad to increase our product presence in Spain and made the right decision to serve the market more effectively by setting up a wholly-owned subsidiary."
The implants for the treatment of prostate cancer are millimeter-sized, weakly radioactive sources which are implanted in the prostate by means of a hollow needle. In contrast to the surgical removal of the prostate, this treatment -being equally effective - causes considerably less incontinence and impotence rates. Prostate cancer is the most frequent cancer for men in Europe with 135,000 new incidences annually.
In combination with special eye applicators, these sources are used to treat eye cancer. Apart from its German and Spanish locations, Eckert & Ziegler maintains offices in Los Angeles, Atlanta, San Francisco, Prague, Paris, Milan und Chennai (India) and employs more than 350 people.
The Board of Directors